HER2 receptor, Nectin‐4, Trop‐2, Tissue factor (TF‐011), and folate receptor (FRα) are all cancer cell surface proteins whose expression is significantly upregulated in their respective cancers, making them prime candidates leading to FDA‐approved ADC therapeutics [12, 13, 14, 15, 16]. Here, TACSTD2 is linked to cancer.